Benzinga | Nov 5, 2020 08:10AM EST

Clovis Oncology Q3 EPS $(0.89) Beats $(0.99) Estimate, Sales $38.77M Miss $42.64M Estimate

Clovis Oncology (NASDAQ:CLVS) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(0.99) by 10.1 percent. This is a 51.89 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $38.77 million which missed the analyst consensus estimate of $42.64 million by 9.07 percent. This is a 3.11 percent increase over sales of $37.60 million the same period last year.